Examiner Cite

5

PTOrSBIGBa (01-10)
Approved for use through 07/31/2012 OMB 0651-031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Remove

Pages,Columns,Lines where

Τ۶

	Application Number		10797981	
	Filing Date		2004-03-04	
NFORMATION DISCLOSURE ITATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor Dennis Eugene Kuhlman		is Eugene Kuhlman	
	Art Unit		1612	
	Examiner Name			
	Attorney Docket Number		9576	

U.S. PATENTS

Name of Patentee or Applicant

Initial*	No	Patent Number	Code ¹	ISSUE L	Jaw	of cited Document		Figures Appear		
	1	6133212		2000-10	D-17	Elliott et al.				
If you wish to add additional U.S. Patent citation information please click the Add button. Add								Add		
U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publica Date	ation	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20040234565		2004-11	1-25	Stella et al.				
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add									
	FOREIGN PATENT DOCUMENTS Remove									
Examiner Initial*		Foreign Document Number ³	Countr Code ²		Kind Code ⁴		Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	т.
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s),

publisher, city and/or country where published.

Examiner Cite

Initials* No

EXAMINER SIGNATURE					
If you wish to add additional non-patent literature document citation information please click the Add button Add					
3	USPTO Non Final Rejection mailed September 27, 2011 in reference to co-pending U.S. Pat. Applin. No. 11/893,347 filed August 15, 2007 (Docket 9576C).				
2	"Particle Size Conversion to Screen Mesh Specification" pgs. 1-2 retrieved online 09/24/11 (http://www.woverwire com/reference/particle-size-print.htm).				
1	Miracare SLB-365 from Rhodia (MSDS retrieved from online of 09/24/11) pgs. 1-9 (222./hodia.com).				

Examiner Signature Date Considered Date Consid

16e Kinz Code of UBPTO Peter Documents at www.UBPTO_COLV or MPET 90104. 2 Enter of this that issued the document, by the involvator code (WPD)
Standard 373.) 3 "The planess patient founds in Counter's, the indicates of the year of the integer of the Emperor must precede the senial number of the patient document.

**Indicate Counter by the appropriate symbols as indicated on the document under WPD Standard 57.6 of possible. **Application is to place a credit number of the patient possible involved the possible. **Application is to place a credit number of the patient possible involved the pasition. **Application is to place a credit number of the patient possible involved the pasition. **Application is to place a credit number of the patient possible involved the patient possi

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10797981	
Filing Date		2004-03-04	
First Named Inventor	Dennis Eugene Kuhlman		
Art Unit		1612	
Examiner Name			
Attorney Docket Number		9576	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97.0F.1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CPR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CPR 1.97(c)(c)

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Matthew A. Molloy/	Date (YYYY-MM-DD)	2011-10-06
Name/Print	Matthew A. Mollov	Registration Number	56415

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1449, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 11, 4, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by whiter a published application, an application open to public inscredience or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.